In someone with a diagnosed deficiency such as iron-deficiency anaemia or B12 deficiency, correcting that deficiency can improve fatigue, and intravenous treatment is established where the oral route has failed. In healthy adults with normal blood results, there is no good-quality trial evidence that a nutrient infusion improves energy — there is essentially no randomised evidence in this group at all. The most-cited placebo-controlled trial of a multi-nutrient infusion was run in people with fibromyalgia rather than healthy volunteers, and found no statistically significant difference from placebo on any outcome measure. Persistent tiredness deserves investigation of its cause rather than an untargeted infusion.

There is no good evidence that it does. A 2022 systematic review of randomised placebo-controlled trials of hangover interventions concluded that only very low quality evidence is available to recommend any pharmacologically active treatment; that review examined active compounds rather than intravenous fluid itself, and no good-quality trial has shown an IV drip to treat a hangover. Intravenous fluid corrects dehydration, which is one component of a hangover, but it does not address the others, and the same rehydration can usually be achieved by drinking.

If the purpose is to correct a deficiency, then yes — a test is what establishes whether the deficiency exists and how significant it is. Giving nutrients for an unmeasured deficiency means treating an assumption, and in the case of iron it can be actively harmful in people with iron overload. A clinician may also want kidney function and other baseline tests depending on what is proposed.

It is a medical procedure with recognised risks rather than a risk-free wellness treatment. Common effects are bruising and pain at the cannula site. Less common but serious risks include infiltration, phlebitis, bloodstream infection, allergic and anaphylactic reactions, fluid overload and electrolyte disturbance, and toxicity from high doses of certain vitamins. Risk is reduced — not eliminated — when infusions are assessed, prepared and given in a properly licensed facility by licensed clinicians.

The infusion itself commonly runs for around thirty to sixty minutes, though some preparations take longer and certain intravenous iron formulations can take several hours. The overall appointment is longer, because it includes consultation, cannulation, monitoring and a short observation period afterwards.

There is no general schedule, because frequency depends on what is being treated. Replacing a diagnosed deficiency follows a course determined by the deficiency, the dose and repeat blood tests. For infusions given without a diagnosed indication, there is no evidence base establishing a beneficial frequency at all, and repeated infusions increase cumulative risk of vein damage, infection and, with fat-soluble vitamins, accumulation.

Components that are prescription medicines require an authorised prescriber, and the decision to administer anything intravenously is a clinical one made after an assessment. In practice this means an infusion should follow a consultation with a licensed clinician rather than being selected by a customer from a menu.

Yes. It is a medical service that must be provided by a health facility licensed by the Dubai Health Authority — or by the relevant free-zone regulator, such as in Dubai Healthcare City — and administered by clinicians holding a current professional licence with the appropriate scope of practice. Health advertising in the UAE is separately regulated.

Home-based intravenous services fall under home-healthcare licensing rules, which set out who may be treated at home and under what conditions. These arrangements exist for patients whose circumstances require care at home rather than as a convenience option. Anyone considering a home infusion should confirm the provider's home-healthcare licence and how a reaction would be managed away from a clinical setting.

Not as a general rule. Intravenous delivery produces higher short-term blood concentrations because it bypasses the gut, and that is genuinely useful where absorption is impaired, where a deficiency needs rapid correction, or where oral treatment has failed. In a person absorbing normally, the oral route is cheaper, carries no cannulation risk, and is adequate for most nutritional needs.

Caution or avoidance applies to people with kidney impairment, heart failure or other fluid-overload risk, uncontrolled hypertension, electrolyte disorders, iron overload conditions such as haemochromatosis, known allergy to an infusion component, or G6PD deficiency where certain high-dose infusions are proposed. Anyone pregnant or breastfeeding should take advice from their treating doctor first. This list is not exhaustive and individual suitability must be assessed by a licensed clinician.

Through a DHA-licensed clinic, after a consultation. Verify the facility and clinician licences, ask what evidence supports the proposed ingredients, and expect the provider to explain oral or no-treatment alternatives. The contents and cost should be determined only after suitability is assessed.